Table 2.
Logistic regressions on percentage of patients with HbA1c < 6.5% | |||
---|---|---|---|
Variable | Odds Ratio | 95% confidence intervals | P-value |
With CVD vs. without CVD | 0.62 | 0.46, 0.82 | 0.001 |
Time indicators | |||
<1 year from index | 6.21 | 3.61, 10.70 | <0.001 |
1-2 years from index | 6.39 | 3.72, 10.98 | <0.001 |
2-3 years from index | 6.69 | 3.81, 11.75 | <0.001 |
3-4 years from index | 7.66 | 4.24, 13.87 | <0.001 |
>= 4 years from index | 5.62 | 3.02, 10.46 | <0.001 |
Variable | Odds Ratio | 95% confidence intervals | P-value |
With CVD vs. without CVD | 0.62 | 0.46, 0.82 | 0.001 |
Study period vs. baseline | 6.47 | 3.71, 11.29 | <0.001 |
Years after the index | 1.00 | 0.92, 1.10 | 0.96 |
Linear regressions on HbA1c (%) | |||
Variable | Coefficient | 95% confidence intervals | P-value |
With CVD vs. without CVD | 0.02 | -0.10, 0.14 | 0.75 |
Time indicators | |||
<1 year from index | -0.80 | -0.97, -0.62 | <0.001 |
1-2 years from index | -0.78 | -0.96, -0.60 | <0.001 |
2-3 years from index | -0.76 | -0.96, -0.57 | <0.001 |
3-4 years from index | -0.88 | -1.07, -0.68 | <0.001 |
>= 4 years from index | -0.84 | -1.07, -0.60 | <0.001 |
Variable | Coefficient | 95% confidence intervals | P-value |
With CVD vs. without CVD | 0.02 | -0.10, 0.14 | 0.75 |
Study period vs. baseline | -0.78 | -0.97, -0.59 | <0.001 |
Years after the index | -0.01 | -0.05, 0.03 | 0.65 |
Note: CVD: cardiovascular diseases. Other controlled covariates in the regression analyses: concurrent treatment of the HbA1c measurement (metformin+SU combination therapy, metformin+glitazones combination therapy, SU monotherapy, glitazones monotherapy, metformin monotherapy, any therapies with insulin), index SU vs. glitazones, age, gender, Caucasian, duration of diabetes, never used alcohol, physical activity, country, BMI, physician specialty.